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Background
As of December 2012, an estimated 35.3 million persons were living with HIV; 
approximately two thirds of these people were living in sub-Saharan Africa.1 The response 
to the HIV pandemic in Africa and in other low-and middle-income regions of the world has 
consisted of a variety of bilateral and multi-lateral support from donor agencies, as well as 
local support from countries that have been able to afford it. A majority of the support has 
been directed towards HIV care and treatment.
Accordingly, the past ten years have witnessed a remarkable increase in the number of HIV-
infected persons receiving antiretroviral therapy (ART) in low- and middle-income 
countries--from 300,000 in 2003 to 9.7 million in 20121,2. Expanded access to ART in these 
countries has led to significant proportions of eligible persons enrolled on ART, reaching 
coverage rates as high as 61% based on the World Health Organization (WHO) treatment 
guidelines eligibility criteria of CD4 <350 cells/uL) in 2012.1 In 2013, WHO revised its 
guidelines to indicate eligibility at CD4 <500 cells/uL; under these criteria, only 34% of 
eligible persons were on ART in 2013.1 Nevertheless, these changes in access to ART were 
estimated to have averted 4.2 million deaths through 20122.1
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HIV treatment programs in low- and middle-income countries have been supported by a 
variety of sources, including over $50 billion through the U.S. President's Emergency Plan 
for AIDS Relief (PEPFAR) from 2004 to 20133. PEPFAR programs are coordinated by the 
U.S. Department of State’s Office of the U.S. Global AIDS Coordinator (OGAC) in 
Washington, D.C.,; oversight of in-country expenditures is supported by additional U.S. 
government(USG) agencies with the majority of funds concentrated in 36 countries and 
regions 4 in sub-Saharan Africa, South and Central Asia, Eastern Europe, Central America 
and the Caribbean. PEPFAR supports a range of HIV care and treatment services besides 
ART including clinical (e.g. monitoring to determine eligibility for ART and prevention and 
treatment of opportunistic infections) and non-clinical services (e.g. psychological, social, 
and preventive)4. Services implemented through PEPFAR support in each country are 
determined through a dialogue between the USG, and host governments. PEPFAR country 
operating plans and budgets are submitted annually and reviewed by USG staff.
In 2013, the U.S. Institute of Medicine (IOM), in its evaluation of PEPFAR, called attention 
to the wide range of non-ART care and support services supported by PEPFAR, and 
challenged PEPFAR to assess the impact of these services on key outcomes. The IOM 
recommended a prioritization of services that should be funded in PEPFAR country 
portfolios5 (IOM, 2013). In response, the PEPFAR Adult Care and Support interagency 
technical working group (TWG) reviewed available evidence on the impact of non-ART 
adult care and support interventions on key outcomes to assist PEPFAR country teams as 
they make care and support program decisions. This paper presents the general approach and 
methods used in these reviews.
METHODS
In late 2013, the PEPFAR Adult Care and Support interagency TWG undertook a review of 
the literature on each of 12 non-ART adult care and support services commonly funded by 
PEPFAR to evaluate the impact of each intervention on five outcomes: mortality, morbidity, 
retention in HIV care, quality of life, and prevention of ongoing HIV transmission. A 13th 
intervention—tuberculosis (TB) screening and treatment--was not reviewed due to the 
abundance of information on this intervention and its recognized importance (and separate 
budget allocations) in PEPFAR programming. A list of the 13 care and support interventions 
(including TB screening and treatment) is shown in Table 1.
Review teams
Review teams were constituted from the PEPFAR Adult Care and Support TWG based on 
technical knowledge and ongoing work related to the respective intervention. Where needed, 
subject matter experts who were not members of the TWG were invited to join the review 
teams. Each review team included at least three reviewers with subject matter expertise. 
These review teams constitute the authorship of the 12 intervention-specific articles in this 
supplement for which a literature review was conducted.
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Search strategy
The following databases were searched to perform this literature review: Medline, Global 
Health, and Embase through Ovid; Cumulative Index to Nursing and Allied Health 
Literature (CINAHL) through EBSCO; Sociological Abstracts (SOCA) through ProQuest; 
and African Index Medicus (AIM) through the WHO. Databases were assessed by librarians 
for their capability to perform complex searches. Aspects of databases considered included 
strength of controlled vocabulary and indexing, advanced search capabilities, and number of 
citations indexed by the database. According to capability, simple searches were performed 
in SOCA and AIM, searches of moderate complexity were performed in CINAHL, and 
searches of the highest complexity were performed in Medline, Embase and Global Health. 
Search terms used to perform the review were agreed upon by members of the review teams 
and two Centers for Disease Control and Prevention (CDC) librarians who performed the 
searches (GB and EW). Terms were intentionally chosen to produce a broad scope of results 
relating to HIV/AIDS and the selected interventions.
Base search strategies were created by the librarians to use across all 12 interventions for 
which the literature was reviewed. These strategies varied according to the capabilities of the 
databases in which they were performed. Simple base strategies, utilized in AIM and SOCA, 
used variations of the terms HIV, human immunodeficiency virus, AIDS, Acquired 
Immunodeficiency Syndrome, and HIV Infections to create filters that addressed HIV/AIDS. 
More complex base strategies, utilized in CINAHL, built upon the simple base by 
introducing a filter that addressed the outcomes of interest including morbidity, mortality, 
retention in care, quality of life, HIV transmission, and cost-effectiveness (Appendix 1). 
Base strategies of the highest complexity, utilized in Medline, Embase and Global Health, 
further added a developing countries or resource-limited settings filter in an effort to limit 
citations to countries and socioeconomic groups of interest to the reviewers (Appendix 2). 
Additionally, base strategies utilized in Medline and Embase applied a humans-only filter 
that was not available in other databases. Further intervention-specific terms were applied to 
these base strategies depending on the intervention and database utilized. These additional 
terms are listed in the papers relating to the individual interventions in this supplement. All 
strategies were initially limited to a date range of January 1995 – July 2013. (Several authors 
updated their literature searches in May 2014; see the intervention-specific articles for 
details.) Results were inclusive of all publication types and languages.
Search results were exported into individual EndNote libraries by database and combined 
into large EndNote libraries by intervention. This enabled the librarians to remove duplicate 
references across databases while maintaining the result counts from individual databases.
EndNote libraries, without duplicates, were exported to Word Documents or sent directly to 
the reviewers based upon software availability and reviewer preference.
Data analysis
For each HIV care and support intervention, reviewers scanned the citations and abstracts to 
identify studies that appeared to address the intervention of interest in persons living with 
HIV (PLHIV) and reported on at least one of the five outcomes of interest (eligible studies). 
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Full-text versions of these studies were obtained and reviewed by the review teams. Studies 
that, upon full review, did not contain this information were excluded from further analysis. 
Those that did meet these criteria were included in the review (included studies).
Rating the quality of evidence for individual studies
The quality of the evidence from each of the included studies for each outcome of interest 
was summarised based on the type of study and other factors, such as the number of study 
participants and internal and external validity of the study data. The overall quality of 
evidence for each study was rated as Strong, Medium or Weak on the basis of these factors 
(Table 2).
Qualitative studies were rated separately using a scale that took into account the research 
design and methodology, theoretical framework, sampling process, methods of data 
collection and analysis, and how authors drew their conclusions6. Based on this scale, 
qualitative studies were rated as either: Level I (Generalizable studies); Level II (Conceptual 
studies); Level III (Descriptive studies); or Level IV (Single case study).
Cost effectiveness
Articles that reported on cost effectiveness were rated separately by a health economist and 
rated as: Level 1 - Full economic evaluation [includes Cost-effectiveness analysis (CEA), 
Cost-utility analysis (CUA), or Cost-benefit analysis (CBA)]; Level 2 - Partial economic 
evaluations (i.e. cost analyses, cost-description studies, cost-outcome descriptions); or Level 
3 - Randomized trials and studies (reporting more limited information, such as estimates of 
resource use or costs associated with the intervention(s) and comparator(s)).
Rating the quality of the body of evidence by outcome
Because of the nature of the review and the review questions as well as the heterogeneity of 
study populations, study methods, settings, and outcomes, we did not attempt quantitative 
synthesis of study results overall. Rather, for each intervention, reviewers applied quality 
measures to each study, grouped the studies by the outcome(s) addressed, and rated the 
overall quality of the body of evidence for each outcome as Good, Fair or Poor (Table 3).
Rating the expected impact by outcome
The expected impact of the intervention by outcome was then determined based on the 
magnitude of effect demonstrated in individual studies, the quality of the body of evidence 
(all included studies), and consistency across the studies. Expected impact was rated as 
High, Moderate, Low or Uncertain based on criteria agreed upon by the TWG a priori (Table 
4). At least two members of each review team participated in assigning expected impact 
ratings for individual outcomes.
Data synthesis
Data from included studies were abstracted and entered into an evidence-rating grid. The 
data elements included: the study identifying information (lead author, title, journal and year 
published); the type of study [e.g., randomized controlled trial (RCT), controlled trial 
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without randomization, observational study, systematic review (with or without meta-
analysis)]; the quality of evidence for each study; the quality of the body of evidence for 
each outcome; the magnitude of effect for each study, presented as hazard ratios, odds ratios, 
or relative risk and 95% confidence intervals; and the overall expected impact for each 
outcome. These evidence rating grids are included in each of the articles in this supplement.
Weekly conference calls coordinated by the Adult Care and Support TWG co-chairs allowed 
reviewers from different groups to share progress to optimize adherence to the same general 
review approach. Each group was asked to summarise their study selection process and 
present it as a studies flow diagram that included: (i) the total number of citations from the 
CDC Library (and other sources, if applicable); (ii) the number of abstracts that were 
deemed eligible for review of the full text articles (eligible studies); (iii) the number of full 
text articles retrieved; (iv) the number of studies excluded upon full text review; and lastly, 
(v) the number of studies that fulfilled the inclusion criteria (included studies). These flow 
diagrams are included in the intervention-specific articles in this supplement.
Reporting the results of the literature reviews
The results of the 12 literature searches and a summary of the literature about TB screening 
are included in the 13 intervention-specific articles in this supplement. Each article contains 
a definition of the intervention of interest; intervention-specific search terms used in the 
review; a flow diagram indicating the process that led to the studies included in the review; 
detailed information on the included studies, including an assessment of the quality of 
evidence and the expected impact of the intervention on each of the outcomes of interest; 
programmatic considerations important in making decisions regarding implementation of the 
intervention; and research or informational gaps.
It is the objective of this review and of the participating authors to present information that 
will be of value not only for PEPFAR in-country USG teams but also for other bi- and multi-
lateral donors and host governments in low- and middle-income countries. Further, the 
authors hope that this information will serve as a resource for discussions on how to 
prioritize HIV care and support funding to maximize the impact of these interventions on the 
HIV/AIDS epidemics in these countries.
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Appendix 1
Filter that addressed the outcomes of interest including morbidity, 
mortality, retention in care, quality of life, HIV transmission, and cost-
effectiveness applied in the base search of the care and support 
intervention evidence review
Variations of the following terms were used to create filters that addressed morbidity, 
mortality, retention in care, quality of life, HIV transmission, and cost-effectiveness in 
CINAHL, Medline, Embase, and Global Health.
access
assessment
cost benefit analysis
cost-effectiveness
death rate
disability-adjusted life year
disease
effect
evaluation
health status
HIV long-term survivors
hospitalization
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illness
impact
independence
independent
interpersonal relations
intervention
morbidity
mortality
outcome
outpatient
people living with HIV
physical condition
physical fitness
prevention
psychological
psychology
quality of life
resources/services
retention
social behavior
social environment
social relationship
transmission
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Appendix 2
Filter for developing countries or resource-limited settings applied in the 
base search of the care and support intervention evidence review
The following filter was created by Mellanye Lackey at the University of North Carolina 
(here). It has been adapted for the purposes of this search.
"developing country" or developing countries or "developing nation" or "developing nations" 
or "developing population"or "developing populations" or "developing world" or "less 
developed country" or "less developed countries" or "less developed nation" or "less 
developed nations" or "less developed population" or "less developed populations" or "less 
developed world" or "lesser developed country" or "lesser developed countries" or "lesser 
developed nation" or "lesser developed nations" or "lesser developed population" or "lesser 
developed populations" or "lesser developed world" or "under developed country" or "under 
developed countries" or "under developed nation" or "under developed nations" or "under 
developed population" or "under developed populations" or "under developed world" or 
"underdeveloped country" or "underdeveloped countries" or "underdeveloped nation" or 
"underdeveloped nations" or "underdeveloped population" or "underdeveloped populations" 
or "underdeveloped world" or "middle income country" or "middle income countries" or 
"middle income nation" or "middle income nations" or "middle income population" or 
"middle income populations" or "low income country" or "low income countries" or "low 
income nation" or "low income nations" or "low income population" or "low income 
populations" or "lower income country" or "lower income countries" or "lower income 
nation" or "lower income nations" or "lower income population" or "lower income 
populations" or "underserved country" or "underserved countries" or "underserved nation" or 
"underserved nations" or "underserved population" or "underserved populations" or 
"underserved world" or "under served country" or "under served countries" or "under served 
nation" or "under served nations" or "under served population" or "under served 
populations" or "under served world" or "deprived country" or "deprived countries" or 
"deprived nation" or "deprived nations" or "deprived population" or "deprived populations" 
or "deprived world" or "poor country" or "poor countries" or "poor nation" or "poor nations" 
or "poor population" or "poor populations" or "poor world" or "poorer country" or "poorer 
countries" or "poorer nation" or "poorer nations" or "poorer population" or "poorer 
populations" or "poorer world" or "developing economy" or "developing economies" or "less 
developed economy" or "less developed economies" or "lesser developed economy" or 
"lesser developed economies" or "under developed economy" or "under developed 
economies" or "underdeveloped economy" or "underdeveloped economies" or "middle 
income economy" or "middle income economies" or "low income economy" or "low income 
economies" or "lower income economy" or "lower income economies" or "low gdp" or "low 
gnp" or "lower gdp" or "lower gnp" or lmic or lmics or "third world" or "lami country" or 
"lami countries" or "transitional country" or "transitional countries" or Africa or Asia or 
Caribbean or West Indies or South America or Latin America or Central America or 
Afghanistan or Albania or Algeria or Angola or Antigua or Barbuda or Argentina or 
Armenia or Armenian or Aruba or Azerbaijan or Bahrain or Bangladesh or Barbados or 
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Benin or Byelarus or Byelorussian or Belarus or Belorussian or Belorussia or Belize or 
Bhutan or Bolivia or Bosnia or Herzegovina or Hercegovina or Botswana or Brazil or 
Bulgaria or Burkina Faso or Burkina Fasso or Upper Volta or Burundi or Urundi or 
Cambodia or Khmer Republic or Kampuchea or Cameroon or Cameroons or Cameron or 
Camerons or Cape Verde or Central African Republic or Chad or Chile or China or 
Colombia or Comoros or Comoro Islands or Comores or Mayotte or Congo or Zaire or 
Costa Rica or Cote d'Ivoire or Ivory Coast or Croatia or Cuba or Cyprus or Czechoslovakia 
or Czech Republic or Slovakia or Slovak Republic or Djibouti or French Somaliland or 
Dominica or Dominican Republic or East Timor or East Timur or Timor Leste or Ecuador or 
Egypt or United Arab Republic or El Salvador or Eritrea or Estonia or Ethiopia or Fiji or 
Gabon or Gabonese Republic or Gambia or Gaza or Georgia Republic or Georgian Republic 
or Ghana or Gold Coast or Greece or Grenada or Guatemala or Guinea or Guam or Guiana 
or Guyana or Haiti or Honduras or Hungary or India or Maldives or Indonesia or Iran or Iraq 
or Jamaica or Jordan or Kazakhstan or Kazakh or Kenya or Kiribati or Korea or Kosovo or 
Kyrgyzstan or Kirghizia or Kyrgyz Republic or Kirghiz or Kirgizstan or "Lao PDR" or Laos 
or Latvia or Lebanon or Lesotho or Basutoland or Liberia or Libya or Lithuania or 
Macedonia or Madagascar or Malagasy Republic or Malaysia or Malaya or Malay or Sabah 
or Sarawak or Malawi or Nyasaland or Mali or Malta or Marshall Islands or Mauritania or 
Mauritius or Agalega Islands or Mexico or Micronesia or Middle East or Moldova or 
Moldovia or Moldovian or Mongolia or Montenegro or Morocco or Ifni or Mozambique or 
Myanmar or Myanma or Burma or Namibia or Nepal or Netherlands Antilles or New 
Caledonia or Nicaragua or Niger or Nigeria or Northern Mariana Islands or Oman or Muscat 
or Pakistan or Palau or Palestine or Panama or Paraguay or Peru or Philippines or Philipines 
or Phillipines or Phillippines or Poland or Portugal or Puerto Rico or Romania or Rumania 
or Roumania or Russia or Russian or Rwanda or Ruanda or "Saint Kitts" or "St Kitts" or 
Nevis or Saint Lucia or St Lucia or "Saint Vincent" or "St Vincent" or Grenadines or Samoa 
or Samoan Islands or Navigator Island or Navigator Islands or Sao Tome or Saudi Arabia or 
Senegal or Serbia or Montenegro or Seychelles or Sierra Leone or Slovenia or Sri Lanka or 
Ceylon or Solomon Islands or Somalia or Sudan or Suriname or Surinam or Swaziland or 
Syria or Tajikistan or Tadzhikistan or Tadjikistan or Tadzhik or Tanzania or Thailand or 
Togo or Togolese Republic or Tonga or Trinidad or Tobago or Tunisia or Turkey or 
Turkmenistan or Turkmen or Uganda or Ukraine or Uruguay or USSR or Soviet Union or 
Union of Soviet Socialist Republics or Uzbekistan or Uzbek or Vanuatu or New Hebrides or 
Venezuela or Vietnam or Viet Nam or West Bank or Yemen or Yugoslavia or Zambia or 
Zimbabwe or Rhodesia or Western Sahara or Kuwait or United Arab Emirates or Qatar or 
Nauru or Tuvalu or Bahamas or South Africa or South Sudan
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Table 1
Care and support interventions included in this supplement
Intervention
1. Cotrimoxazole (CTX) prophylaxis
2. Tuberculosis screening
3. Isoniazid preventive therapy (IPT)
4. Positive Health, Dignity, and Prevention (PHDP)/Prevention with Positives (PwP)
5. Viral hepatitis—hepatitis B virus (HBV) surface antigen screening
6. Malaria prevention (cotrimoxazole and insecticide treated nets)
7. Safe Water, Sanitation and Hygiene (WASH)
8. Prevention of cryptococcal meningitis (cryptococcal antigen screening and treatment)
9. Nutritional Assessment, Counseling and Support (NACS)
10. Screening and treatment to prevent cervical cancer
11. Mental health and substance/alcohol abuse
12. Social services
13. Support groups
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Table 2
Criteria for rating the quality of evidence* for individual studies
Level of evidence Description
1=STRONG Systematic review/meta-analysis of randomized controlled trials (RCTs) with consistent findings; high-quality individual 
RCT
2=MEDIUM Systematic review/meta-analysis of lower-quality clinical trials or of studies with inconsistent findings; lower-quality 
clinical trial; cohort study; case-control study
3=WEAK Consensus guidelines; usual practice; expert opinion; case series
*Criteria for rating the quality of evidence for each study were adapted from the U.S. Preventive Services Task Force Procedure Manual7. For 
purposes of these reviews, ratings could be modified by other factors, including the number of study participants and an assessment of the internal 
and external validity of the study data.
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Table 3
Criteria for rating the quality of the body of evidence* by outcome of interest
Rating Description
1= GOOD Evidence includes consistent results from well-designed, well-conducted studies in representative populations that directly assess 
effects on health outcomes
2= FAIR: Evidence is sufficient to determine effects on health outcomes, but the strength of the evidence is limited by the number, quality, 
or consistency of the individual studies, generalizability to routine practice, or indirect nature of the evidence on health outcomes.
3= POOR Evidence is based on consensus, usual practice, opinion, or case series. Additionally evidence is insufficient to fully assess the 
effects on health outcomes because of limited number, or power of studies, important flaws in design or conduct, gaps in the 
chain of evidence, or lack of information on importance on the key health outcomes
*Adapted from the US Preventive Services Task Force Procedure Manual7.
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Table 4
Criteria for rating the expected impact of the intervention on the outcome of interest
Rating Description
1= HIGH Intervention expected to have a high impact on the outcome
2= MODERATE Intervention likely to have a moderate impact on the outcome
3= LOW Intervention expected to have a low impact on the outcome
4=UNCERTAIN Available information is not adequate to assess impact on the outcome
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